COMPLEX ORGANOPROTECTION OF CARVEDILOL BY ARTERIAL HYPERTENSION OF 1-2ND DEGREE, COMBINED WITH THE METABOLIC SYNDROME

Matrosova Irina Borisovna, Candidate of medical sciences, associate professor, sub-department of therapeutics, Medical institute, Penza State University, terapia-pgu@rambler.ru
Eliseeva Irina Vladimirovna, Postgraduate student, Medical institute, Penza State University, eliseeva-terapia@rambler.ru
Gusakovskaya Lyudmila Ivanovna, Postgraduate student, Medical institute, Penza State University, terapia-pgu@rambler.ru
Borisocheva Nadezhda Valeryevna, Postgraduate student, Medical institute, Penza State University, terapia-pgu@rambler.ru
Oleynikov Valentin Elivich, Doctor of medical sciences, professor, head of therapeutics sub-department, Medical institute, Penza State University, oleynikoff@sura.ru

616.12-008.331.1

In open prospective 16-week study the assessment of clinical efficiency, vaso- and cardioprotective properties of carvedilol (not selective a, b-blocker) was performed. Carvedilol was used in the form of monotherapy and application in a combination to nifedipine or in the form of a combination of the specified preparations with metformin and simvastatin. Carvedilol both monotherapy and at application with nifedipine normalises blood pressure irrespective of number of risk factors. It is revealed expressed cardio- and vasoprotective action without negative influence on carbohydrate and lipid metabolism.

metabolic syndrome, carvetrend, cardioprotection, vasoprotection, sym-pathetic nervous system.